Author:
Schneider Christian K, ,Borg John J,Ehmann Falk,Ekman Niklas,Heinonen Esa,Ho Kowid,Hoefnagel Marcel H,van der Plas Roeland Martijn,Ruiz Sol,van der Stappen Antonius J,Thorpe Robin,Tiitso Klara,Tsiftsoglou Asterios S,Vleminckx Camille,Waxenecker Guenter,Welin Mats,Weise Martina,Trouvin Jean-Hugues,
Publisher
Springer Science and Business Media LLC
Subject
Biomedical Engineering,Molecular Medicine,Applied Microbiology and Biotechnology,Bioengineering,Biotechnology
Reference11 articles.
1. Schneider, C. et al. Nat. Biotechnol. 30, 744–746 (2012).
2. Schellekens, H. & Moors, E. Nat. Biotechnol. 28, 28–31 (2010).
3. European Medicine Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues EMEA/CHMP/BWP/49348/2005 (2006).
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003953.pdf
4. European Medicine Agency. Withdrawal assessment report Marvel insulin (2010).
http://www.ema.europa.eu/docs/en_GB/document_library/Application_withdrawal_assessment_report/2010/01/WC500067086.pdf
5. European Medicines Agency. European public assessment report (EPAR) for Alpheon (2007).
http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/000585/WC500017451.pdf
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献